First CTE diagnosis in living former NFL player confirmed, but questions remain

The first diagnosis in a living patient of the dementia type that’s been hitting one former NFL player after the next—chronic traumatic encephalopathy, or CTE—has been documented.

In a study published this week in Neurosurgery, researchers describe their work using PET with the radiotracer FDDNP to see the damaging tau proteins in vivo.

The study’s lead author, Bennet Omalu, MD, MPH, tells CNN that the affected player was Fred McNeill, who played linebacker for the Minnesota Vikings for 12 years.

McNeill retired in 1985, was diagnosed in 2012 and died in 2015. His CTE was confirmed by autopsy.

Covering the development for CNN, Sanjay Gupta, MD, notes that only 14 NFL players have been examined with FDDNP-PET, and only McNeill’s has been confirmed.

Gupta also points out that much research remains to be done.

“The question is, will the test be able to distinguish CTE from other dementias,” he says, “like Alzheimer’s?”

Get the rest:

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.